secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001104659-24-055981
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics Q1 net loss narrows to $26.6M; cash $457M; Phase 2/3 trial initiated
--------------------------------------------------------------------------------

- Cash and equivalents $457.0M as of Mar 31, 2024, down from $526.4M at Dec 31, 2023.
- Net loss of $26.6M ($0.62 per share) vs $39.1M ($1.30) in Q1 2023; improvement helped by $8.2M retroactive UK R&D tax credits.
- R&D expenses rose to $34.9M from $32.2M YoY, driven by BT8009 clinical program costs.
- Initiated Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer; enrollment ongoing.
- Mike Hannay promoted to Chief Product and Supply Chain Officer; multiple clinical data readouts expected in 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465924055981/0001104659-24-055981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465924055981/tm2413108d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-055981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer